Mir Amaan Ali1, Brian R Hirshman1, Bayard Wilson1, Kate T Carroll1, James A Proudfoot2, Steven J Goetsch3, John F Alksne1, Kenneth Ott3, Hitoshi Aiyama4, Osamu Nagano5, Bob S Carter1, Gerald Fogarty6, Angela Hong6, Toru Serizawa7, Masaaki Yamamoto4, Clark C Chen8. 1. Center for Translational and Applied Neuro-Oncology, Department of Neurosurgery, University of California, San Diego, La Jolla, California, USA. 2. Clinical and Translational Research Institute, University of California, San Diego, San Diego, California, USA. 3. San Diego Gamma Knife Center, La Jolla, California, USA. 4. Katsuta Hospital Mito GammaHouse, Hitachi-Naka, Japan. 5. Gamma Knife House, Chiba Cerebral and Cardiovascular Center, Ichihara, Japan. 6. Melanoma Institute of Australia, Sydney, Australia. 7. Tsukiji Neurological Clinic, Tokyo Gamma Unit Center, Tokyo, Japan. 8. Center for Translational and Applied Neuro-Oncology, Department of Neurosurgery, University of California, San Diego, La Jolla, California, USA; Department of Neurosurgery, University of Minnesota, Minneapolis, Minnesota, USA. Electronic address: ccchen@umn.edu.
Abstract
BACKGROUND: The number of brain metastases (BMs) plays an important role in the decision between stereotactic radiosurgery (SRS) and whole-brain radiation therapy. METHODS: We analyzed the survival of 5750 SRS-treated patients with BM as a function of BM number. Survival analyses were performed with Kaplan-Meier analysis as well as univariate and multivariate Cox proportional hazards models. RESULTS: Patients with BMs were first categorized as those with 1, 2-4, and 5-10 BMs based on the scheme proposed by Yamamoto et al. (Lancet Oncology 2014). Median overall survival for patients with 1 BM was superior to those with 2-4 BMs (7.1 months vs. 6.4 months, P = 0.009), and survival of patients with 2-4 BMs did not differ from those with 5-10 BMs (6.4 months vs. 6.3 months, P = 0.170). The median survival of patients with >10 BMs was lower than those with 2-10 BMs (6.3 months vs. 5.5 months, P = 0.025). In a multivariate model that accounted for age, Karnofsky Performance Score, systemic disease status, tumor histology, and cumulative intracranial tumor volume, we observed a ∼10% increase in hazard of death when comparing patients with 1 versus 2-10 BMs (P < 0.001) or 10 versus >10 BMs (P < 0.001). When BM number was modeled as a continuous variable rather than using the classification by Yamamoto et al., we observed a step-wise 4% increase in the hazard of death for every increment of 6-7 BM (P < 0.001). CONCLUSIONS: The contribution of BM number to overall survival is modest and should be considered as one of the many variables considered in the decision between SRS and whole-brain radiation therapy.
BACKGROUND: The number of brain metastases (BMs) plays an important role in the decision between stereotactic radiosurgery (SRS) and whole-brain radiation therapy. METHODS: We analyzed the survival of 5750 SRS-treated patients with BM as a function of BM number. Survival analyses were performed with Kaplan-Meier analysis as well as univariate and multivariate Cox proportional hazards models. RESULTS:Patients with BMs were first categorized as those with 1, 2-4, and 5-10 BMs based on the scheme proposed by Yamamoto et al. (Lancet Oncology 2014). Median overall survival for patients with 1 BM was superior to those with 2-4 BMs (7.1 months vs. 6.4 months, P = 0.009), and survival of patients with 2-4 BMs did not differ from those with 5-10 BMs (6.4 months vs. 6.3 months, P = 0.170). The median survival of patients with >10 BMs was lower than those with 2-10 BMs (6.3 months vs. 5.5 months, P = 0.025). In a multivariate model that accounted for age, Karnofsky Performance Score, systemic disease status, tumor histology, and cumulative intracranial tumor volume, we observed a ∼10% increase in hazard of death when comparing patients with 1 versus 2-10 BMs (P < 0.001) or 10 versus >10 BMs (P < 0.001). When BM number was modeled as a continuous variable rather than using the classification by Yamamoto et al., we observed a step-wise 4% increase in the hazard of death for every increment of 6-7 BM (P < 0.001). CONCLUSIONS: The contribution of BM number to overall survival is modest and should be considered as one of the many variables considered in the decision between SRS and whole-brain radiation therapy.
Authors: Michael T Milano; Veronica L S Chiang; Scott G Soltys; Tony J C Wang; Simon S Lo; Alexandria Brackett; Seema Nagpal; Samuel Chao; Amit K Garg; Siavash Jabbari; Lia M Halasz; Melanie Hayden Gephart; Jonathan P S Knisely; Arjun Sahgal; Eric L Chang Journal: Neuro Oncol Date: 2020-12-18 Impact factor: 12.300
Authors: Eric W Sankey; Vadim Tsvankin; Matthew M Grabowski; Gautam Nayar; Kristen A Batich; Aida Risman; Cosette D Champion; April K S Salama; C Rory Goodwin; Peter E Fecci Journal: Cancer Med Date: 2019-09-30 Impact factor: 4.452
Authors: Manmeet Ahluwalia; Mir A Ali; Rushikesh S Joshi; Eun Suk Park; Birra Taha; Ian McCutcheon; Veronica Chiang; Angela Hong; Georges Sinclair; Jiri Bartek; Clark C Chen Journal: Neurooncol Adv Date: 2020-11-12
Authors: Raquel Blazquez; Martin Andreas Proescholdt; Marlene Klauser; Karl-Michael Schebesch; Christian Doenitz; Daniel Heudobler; Lena Stange; Markus J Riemenschneider; Elisabeth Bumes; Katharina Rosengarth; Andreas Schicho; Nils-Ole Schmidt; Alexander Brawanski; Tobias Pukrop; Christina Wendl Journal: Front Oncol Date: 2022-04-04 Impact factor: 5.738
Authors: Michael H Soike; Ryan T Hughes; Michael Farris; Emory R McTyre; Christina K Cramer; J D Bourland; Michael D Chan Journal: Neurosurgery Date: 2019-03-01 Impact factor: 5.315
Authors: Martin A Proescholdt; Petra Schödel; Christian Doenitz; Tobias Pukrop; Julius Höhne; Nils Ole Schmidt; Karl-Michael Schebesch Journal: Cancers (Basel) Date: 2021-03-31 Impact factor: 6.639